Skeletal and mineral metabolic effects of risedronate in a rat model of high-turnover renal osteodystrophy

[11] Jamal SA(2007)Fracture risk after parathyroidectomy among chronic hemodialysis patients J Am Soc Nephrol 18 2401-2407

[12] Antoniucci DM(2013)Trends in hip fracture rates in US hemodialysis patients, 1993–2010 Am J Kidney Dis 62 747-754

[13] Cummings SR(2018)Hip fracture trends in Japanese dialysis patients, 2008–2013 Am J Kidney Dis 71 173-181

[14] Tentori F(1999)Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial JAMA 282 1344-1352

[15] McCullough K(2001)Effect of risedronate on the risk of hip fracture in elderly women N Engl J Med 344 333-340

[16] Kilpatrick RD(2005)Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials J Bone Miner Res 20 2105-2115

[17] Bradbury BD(2000)Short-term administration of the bisphosphonate ibandronate increases bone volume and prevents hyperparathyroid bone changes in mild experimental renal failure Clin Nephrol 54 45-53

[18] Robinson BM(2005)Changes in bone volume and bone resorption by olpadronate treatment in an experimental model of uremic bone disease J Musculoskelet Nueronal Interact 5 174-181

[19] Kerr PG(2008)Treatment of experimental renal osteodystrophy with pamidronate Kidney Int 74 319-327

[20] Pisoni RL(2009)Effect of bisphosphonates on vascular calcification and bone metabolism in experimental renal failure Kidney Int 75 617-625

[11] Jamal SA(2007)Fracture risk after parathyroidectomy among chronic hemodialysis patients J Am Soc Nephrol 18 2401-2407

[12] Antoniucci DM(2013)Trends in hip fracture rates in US hemodialysis patients, 1993–2010 Am J Kidney Dis 62 747-754

[13] Cummings SR(2018)Hip fracture trends in Japanese dialysis patients, 2008–2013 Am J Kidney Dis 71 173-181

[14] Tentori F(1999)Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial JAMA 282 1344-1352

[15] McCullough K(2001)Effect of risedronate on the risk of hip fracture in elderly women N Engl J Med 344 333-340

[16] Kilpatrick RD(2005)Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials J Bone Miner Res 20 2105-2115

[17] Bradbury BD(2000)Short-term administration of the bisphosphonate ibandronate increases bone volume and prevents hyperparathyroid bone changes in mild experimental renal failure Clin Nephrol 54 45-53

[18] Robinson BM(2005)Changes in bone volume and bone resorption by olpadronate treatment in an experimental model of uremic bone disease J Musculoskelet Nueronal Interact 5 174-181

[19] Kerr PG(2008)Treatment of experimental renal osteodystrophy with pamidronate Kidney Int 74 319-327

[20] Pisoni RL(2009)Effect of bisphosphonates on vascular calcification and bone metabolism in experimental renal failure Kidney Int 75 617-625